Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Impact of type 2 Diabetes and Metformin use on Vitamin B12 Associated Biomarkers - an Observational Study
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4492893
Author(s) Metaxas, Corina; Zurwerra, Chantal; Rudofsky, Gottfried; Hersberger, Kurt E.; Walter, Philipp N.
Author(s) at UniBasel Hersberger, Kurt
Metaxas, Corina
Walter, Philipp
Year 2018
Title Impact of type 2 Diabetes and Metformin use on Vitamin B12 Associated Biomarkers - an Observational Study
Journal Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Volume 126
Number 6
Pages / Article-Number 394-400
Mesh terms Aged; Biomarkers, blood, metabolism; Cross-Sectional Studies; Diabetes Mellitus, Type 2, blood, complications, drug therapy, epidemiology; Female; Humans; Male; Metformin, therapeutic use; Middle Aged; Switzerland, epidemiology; Vitamin B 12, blood, metabolism; Vitamin B 12 Deficiency, blood, complications, epidemiology
Abstract Assessment of the impact of type 2 diabetes (T2DM) and metformin use on vitamin B12 (VB12) associated biomarkers and their suitability to represent VB12 supply.; Differences of VB12, holotranscobalamine (HoloTc), the biologically active fraction (%AB12)=HoloTc/VB12*100 and homocystein (Hcy) were analysed i) among diabetic outpatients with (DMMet+ ) and without metformin use (DMMet-) and ii) in comparison to an external non-diabetic reference group with low VB12 (<200 pmol/L).; VB12 associated biomarkers were distributed equally between DMMet+  (n=29, 58%) and DMMet- (n=21, 42%). Significant differences in %AB12 in diabetic patients with low VB12 (n=19) compared to the non-diabetic reference group (n=31) were found. Higher %AB12 was associated with diabetes. Hcy levels were significantly associated with age, folic acid level, renal function and HoloTc but not with VB12.; In T2DM patients with low VB12, %AB12 was confirmed as being higher in comparison to nondiabetic patients. The effect was not clearly attributable to metformin use. HoloTc was unaffected by the lowering of VB12 and significantly associated with the functional marker Hcy. Both findings support the use of HoloTc for the assessment of VB12 supply in diabetic patients.
Publisher JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
ISSN/ISBN 1439-3646
URL https://www.ncbi.nlm.nih.gov/pubmed/29396969
edoc-URL https://edoc.unibas.ch/68216/
Full Text on edoc No
Digital Object Identifier DOI 10.1055/s-0043-120760
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/29396969
ISI-Number WOS:000435299900010
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.313 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
19/05/2024